Dit zijn documenten die op last van een USA rechter openbaar zijn gemaakt door Monsanto. Meer dan 285 aanklachten zijn er ingediend tegen Monsanto in de District Court (rechtbank) in San Francisco. Het nummer van de zaak is 3:16-md-02741-VC. De behandeling van de eerste zaak zal op 18 juni 2018 plaatsvinden. De aanklachten komen van mensen waarvan zij of hun familieleden kanker zouden hebben gekregen van het blootstellen aan het onkruidbestrijdingsmiddel Roundup. De zaken worden gecombineerd afgehandeld als multidistrict procesvoering onder rechter Vince Chhabria. Monsanto heeft altijd gezegd dat Roundup onschadelijk is voor de gezondheid en het milieu, terwijl ze beter wisten. Advocaten schatten dat hierna nog ongeveer 3.500 mensen een soortgelijke claim ingediend hebben in andere staten van de USA (Engelse tekst).

The Monsanto Papers: MDL Glyphosate Cancer Case Key Documents & Analysis

More than 285 lawsuits are pending against Monsanto Co. in U.S. District Court in San Francisco, filed by people alleging that exposure to Roundup herbicide caused them or their loved ones to develop non-Hodgkin lymphoma, and that Monsanto covered up the risks. The cases have been combined for handling as multidistrict litigation under Judge Vince Chhabria. The lead case is 3:16-md-02741-VC. Additionally, thousands of other plaintiffs have made similar claims against Monsanto in state courts. Plaintiffs’ attorneys estimate the total number of plaintiffs at approximately 3,500. The first trial in the Roundup litigation is set for June 18, 2018 in the Superior Court for the County of San Francisco.

On March 13th, 2017, U.S. District Judge Vince Chhabria ruled — over Monsanto’s objections — that certain documents obtained by plaintiffs through discovery could be unsealed. The documents listed below include discovery materials, transcripts of court proceedings, depositions and other case-related items.

As of Nov. 20, 2017, the schedule for adjudication of the MDL litigation is:

Science Week – Live testimony from witnesses set for the week of March 5, 2018, with argument from counsel to take place during the week of March 12 or the week of March 19. Claims Construction Hearing set for 3/5/2018 through 3/9/2018 09:00 AM. Motion Hearing: MOTION for Summary Judgment and Daubert Motion on General Causation set for 3/5/2018 09:00 AM in Courtroom 4, 17th Floor, San Francisco before Judge Vince Chhabria.

A joint committee of the European Parliament held a hearing into the revelations contained in the discovery documents obtained through the MDL litigation on Oct. 11. The agenda can be seen here. More details are here and available here.

TOP NEWS

My Friend Died From Cancer Today

December 18, 2017

The Rise of Anti-Women, Anti-Public Health Groups

November 30, 2017

Carey Gillam’s presentation to European Parliament glyphosate hearing: Revelations from Monsanto Papers and Other Research

October 12, 2017

COURT AND DISCOVERY DOCUMENTS

· Conditional Transfer Order Dec. 18, 2017 (2 pages) (12.18.17)

· Pre-trial order re Daubert (1 page) (12.14.17)

· Conditional Transfer Order Nov. 22, 2017 (2 pages) (11.22.17)

· Saltmiras, Kier Kirkland discussion of authorship of paper (6 pages) (11.20.17)

· Monsanto strategy discussion re IARC (12 pages) (11.20.17)

· Monsanto Exponent Ag Health Study analysis (119 pages) (11.20.17)

· Exponent report to CropLife on epidemiology studies (41 pages) (11.20.17)

· Industry farm family exposure task force report 2000 (10 pages) (11.20.17)

· Plaintiffs reply opposing Monsanto motion for summary judgment (25 pages) (11.20.17)

· Acquavella report on Ag Health Study 1997 (6 pages) (11.20.17)

· Monsanto answer to complaint Arthur Sweat (24 pages) (11.20.17)

· Monsanto memo 1985 re mouse study (3 pages) (11.20.17)

· Judge orders change of schedule for Daubert hearing (1 page) (11.17.17)

· Plaintiffs’ letter on impacts of AHS on Daubert issue (5 pages) (11.14.17)

· Monsanto letter on impacts of AHS on Daubert issue (5 pages) (11.14.17)

· Conditional transfer order (2 pages) (11.14.17)

· Monsanto answer to plaintiff Votta’s complaint (25 pages) (11.13.17)

· Conditional transfer order (2 pages) (11.13.17)

· Monsanto reply in support of motion for summary judgment (154 pages) (11.10.17)

· Pretrial Order Re Ag Health Study and Daubert Hearing (1 page) (11.10.17)

· Transcript of Nov. 9, 2017 case management conference (35 pages) (11.9.17)

· Monsanto’s answer to Pearce complaint (25 pages) (11.6.17)

· Monsanto’s answer to Scott amended complaint (36 pages) (11.6.17)

· Transfer order Nov 6. 2017 (2 pages) (11.6.17)

· Judge’s order to remove incorrectly filed documents (1 page) (11.3.17)

· Corrected Exhibit Nos 27 and 88 (43 pages) (11.1.17)

· Joint Case Management Statement Nov. 2, 2017 (3 pages) (11.2.17)

· Motion to file under seal Nov. 1 2017 (125 pages) 11.1.17)

· Motion to remove incorrectly filed documents (3 pages) (11.1.17)

· Conditional Transfer Order Oct. 30 (2 pages) (10.30.17)

· Exact Analysis of Dose Response for Multiple Correlated Binary Outcomes (344 pages) (10.28.17)

· EPA cooperation with EFSA (3 pages) (10.28.17)

· Deposition of Christopher Corcoran (354 pages) (10.28.17)

· Deposition of Warren Foster (270 pages) (10.28.17)

· Dr. Goodman’s references for Ames GBF Data Set (7 pages) (10.28.17)

· Comparison of the in vivo and in vitro genotoxicity of glyphosate (8 pages) (10.28.17)

· Correspondence between plaintiff and defense attorneys re missing rodent studies (4 pages) (10.28.17)

· Law firm request for all study documents (3 pages) (10.28.17)

· Solomon and IARC disagreement on research (5 pages) (10.28.17)

· expert report of Jennifer Rider (92 pages) (10.28.17)

· Bolognesi -Micronuclei and pesticide exposure (9 pages) (10.28.17)

· 2001 Monsanto discussions of glyphosate issues (3 pages) (10.28.17)

· Deposition of Matthew Ross and related documents (398 pages) (10.28.17)

· Baseline determination, glyphosate aerial spraying on Ecuadorian border (8 pages) (10.28.17)

· Biomonitoring of Genotoxic Risk in Columbia Exposure to Glyphosate (14 pages) (10.28.17)

· 2001 Monsanto discussions of glyphosate issues (3 pages) (10.28.17)

· Payment for Keith Solomon (3 pages) (10.28.17)

· Evaluation of DNA damage in Ecuadorian population exposed to glyphosate (6 pages) (10.28.17)

· Best practices for use of historical control data (17 pages) (10.28.17)

· Statistical tests, P values, confidence intervals and power (15 pages) (10.28.17)

· Mode of Action analysis for liver tumors (16 pages) (10.28.17)

· Update Mode of Action for liver tumors paper (12 pages) (10.28.17)

· Lymphomas and leukemias in mice paper (6 pages) (10.28.17)

· Finding Mouse Models of Human Lymphomas paper (10 pages) (10.28.17)

· R elevance of Animal Carcinogenesis Findings paper (10 pages) (10.28.17)

· Deposition of Charles Jameson (217 pages) (10.28.17)

· Rebuttal report of chris portier (38 pages) (10.28.17)

· Chris Portier expert report (97 pages) (10.28.17)

· Portier related documents and contract (304 pages) (10.28.17)

· Portier communications and documents (347 pages) (10.28.17)

· Spontaneous neoplastic lesions in CD-1 Mice March 2000 (154 pages) (10.28.17)

· Expert report of Christopher Corcoran (82 pages) (10.28.17)

· Portier and IARC related documents (414 pages) (10.28.17)

· Monsanto communications 2003 re JMPR information (5 pages) (10.28.17)

· Transcript Feb. 24, 2017 hearing (38 pages) (10.28.17)

· Monsanto communications on decision not to repeat rat skin study (4 pages) (10.28.17)

· Glyphosate formulations testing for dermal uptake Monsanto Brussels (7 pages) (10.28.17)

· 2002 Monsanto absorption study on rat skin (37 pages) (10.28.17)

· Monsanto discussion of dermal absorption and urine excretion study concerns (8 pages) (10.28.17)

· Glyphosate skin binding, absorption paper (9 pages) (10.28.17)

· Dermal absorption monkey study (16 pages) (10.28.17)

· Monsanto communications re dermal uptake, excretion (3 pages) (10.28.17)

· Briefing on IARC evaluation CropLife requested meetings (4 pages) (10.28.17)

· Key Characteristics of Carcinogens paper (306 pages) (10.28.17)

· Evaluation of Medical Conditions Associated with Risk of NHL (138 pages) (10.28.17)

· Rothman Six Persistent Research Misconceptions paper (6 pages) (10.28.17)

· AHS Heltshe paper (20 pages) (10.28.17)

· Communications re rejection of Alavanja AHS paper (4 pages) (10.28.17)

· Alavanja paper NHL risk in AHS (18 pages) (10.28.17)

· PLOS ONE revisions requested for Alavanja paper (15 pages) (10.28.17)

· Portier paper Differences in evaluations of IARC and EFSA (8 pages) (10.28.17)

· Impact of pesticide exposure misclassification AHS (14 pages) (10.28.17)

· Cancer incidence among glyphosate-exposed pesticide applicators in AHS (7 pages) (10.28.17)

· AHS critical review with suggested improvements (25 pages) (10.28.17)

· Monsanto communications re concerns over Hardell research (7 pages) (10.28.17)

· Rough draft NHL proposal for ECPA (6 pages) (10.28.17)

· Chang and Delzell 2016 meta analysis of glyphosate exposure and cancer risks (29 pages) (10.28.17)

· Review and meta-analysis NHL and exposure to pesticides (80 pages) (10.28.17)

· Evaluation of glyphosate use and risk of NHL in North American Pooled Project (20 pages) (10.28.17)

· Detailed assessment North American Pooled Project (2 pages) (10.28.17)

· Expert report problems with AHS study (14 pages) (10.28.17)

· Assessment glyphosate North American Pooled Project (2 pages) (10.28.17)

· NAPP evaluation of glyphosate use shows evidence of association with NHL (2 pages) (10.28.17)

· Hardell Eriksson and Nordstrom paper 2001 pesticide exposure risk (10 pages) (10.28.17)

· NHL and pesticide exposure Canada study (11 pages) (10.28.17)

· Deposition of Beate Ritz with related documents (806 pages) (10.28.17)

· Deposition of Dennis Weisenburger and related papers (569 pages) (10.28.17)

· Exponent meta-analysis of glyphosate use and risk of NHL (13 pages) (10.28.17)

· De Roos 2003 paper on pesticides as risk factors for NHL (11 pages) (10.28.17)

· Eriksson paper on pesticide exposure risk factor for NHL (8 pages) (10.28.17)

· Manuscript submission requirements for biomedical publications (101 pages) (10.28.17)

· Expert report of Monsanto witness Jennifer Rider (201 pages) (10.28.17)

· Bolognesi paper on monitoring pesticide exposed populations (166 pages) (10.28.17)

· North American Pooled Project paper on NHL and glyphosate (107 pages) (10.28.17)

· Cancer related scientific papers (172 pages) (10.28.17)

· Deposition of Monsanto expert witness Jennifer Rider (114 pages) (10.28.17)

· Manuscripts on AHS, IARC, BfR, EFSA (121 pages) (10.28.17)

· Draft of AHS lymphoma risk and pesticide use paper (97 pages) (10.28.17)

· Deposition of John Acquavella with related research papers (82 pages) (10.27.17)

· 2014 paper on NHL and exposure to pesticides (102 pages) (10.28.17)

· Expert report of Monsanto witness Lorelei Mucci (150 pages) (10.28.17)

· Swiss study and others attached to Neugut deposition (467 pages) (10.28.17)

· Deposition of Monsanto expert witness Lorelei Mucci (111 pages) (10.28.17)

· Lymphoma risk and pesticide use Agricultural Health Study (175 pages) 10.28.17)

· Correspondence IARC Aaron Blair (77 pages) (10.28.17)

· IARC monographs on the evaluation of carcinogenic risks to humans (132 pages) (10.28.17)

· Post IARC discussion Monsanto re classification (8 pages) (10.27.17)

· Bradford Hill 1965 (7 pages) (10.27.17)

· IARC monographs 40 years of evaluating carcinogenic hazards (9 pages) (10.27.17)

· Email EPA Jess Rowland discusses IARC finding before it is made public (3 pages) (10.27.17)

· Monsanto 2014 discussion of vulnerability with IARC (2 pages) (10.27.17)

· Monsanto IARC preparedness plan (4 pages) (10.27.17)

· Review of genotoxicity studies Kier and Kirkland 2013 (35 pages) (10.27.17)

· Review of genotoxicity summary (2 pages) (10.27.17)

· Monsanto manuscript clearance form (6 pages) (20.27.17)

· Emails discussing Monsanto hiring Kirkland (15 pages) (10.27.17)

· Expert witness report Warren Foster (120 pages) (10.27.17)

· Glyphosate review genotoxicity oxidative stress data (176 pages) (10.27.17)

· Monsanto planning for IARC discussions with Acquavella (4 pages) (10.27.17)

· Evaluation of potential genotoxicity of glyphosate by James Parry (52 pages) (10.27.17)

· Partial release Videotaped deposition of Mark Martens (6 pages) (10.27.17)

· Wiliams Kroes & Munro (50 pages) (10.27.17)

· Monsanto emails re IARC preparations (8 pages) (10.27.17)

· Donna Farmer emails re testing on Roundup (4 pages) (10.27.17)

· Monsanto emails re 1999 scientific papers (2 pages) (10.27.17)

· Monsanto discussion of glyphosate publications recommendations for process (7 pages) (10.27.17)

· Monsanto email glyphosate toxicology activities (3 pages) (10.27.17)

· Discussion of 1985 tumors in mice (5 pages) (10.27.17)

· Monsanto correspondence to California April 1987 on mouse study (3 pages) (10.27.17)

· Memo to EPA from Kasza 1985 on mouse tumors (2 pages) (10.27.17)

· EPA summary of IBT review program (47 pages) (10.27.17)

· US Patent Office Document (2 pages) (10.27.17)

· Heydens email on issues faced in early glyphosate days (2 pages) (10.27.17)

· Monsanto 1985 correspondence on feeding study in mice (13 pages) (10.27.17)

· Monsanto Action Plan ECHA (4 pages) (10.27.17)

· Monsanto talking points for EPA meeting (4 pages) (10.27.17)

· ATSDR Glyphosate review emails (3 pages) (10.27.17)

· EPA SAP December 2016 meeting minutes (102 pages) (10.27.17)

· DynCorp case Expert Witness report (46 pages) (10.27.17)

· Declaration of Aimee Wagstaff related to Daubert and Summary Judgment Motion (11 pages) (10.27.17)

· Plaintiff’s opposition to Monsanto’s summary judgment motion (79 pages) (10.27.17)

· Motion to file under seal re Daubert (79 pages) (10.27.17)

· Oct. 25 Transfer Order (2 pages) (10.25.17)

· Joint case management statement (6 pages) (10.20.17)

· Monsanto’s Answer to Complaint by Tara L. DiVittorio (37 pages) (10.13.17)

· MONSANTO’S WITNESS LIST FOR DAUBERT HEARING (9 pages) (10.13.17)

· State Court cases notification (6 pages) (10.9.17)

· Lawyer Letter re Portier citations (2 pages) (10.6.17)

· Expert Report of Chris Portier (250 pages) (10.6.17)

· Expert Report of Lorelei Mucci (150 pages) (10.6.17)

· Deposition of Dennis Weisenburger Sept. 2017 (101 pages) (10.6.17)

· May 2017 Deposition of Matthew Ross (118 pages) (10.6.17)

· May 2017 Deposition of Charles Jameson (133 pages) (10.6.17)

· Deposition of Beate Ritz (163 pages) (10.6.17)

· Expert Report of Dennis Weisenburger (150 pages) (10.6.17)

· Expert Report of Alfred Neugut (127 pages) (10.6.17)

· Expert Report of Chadi Nabhan (61 pages) (10.6.17)

· Beate Ritz Expert Report (73 pages) 10.6.17)

· Transcript of Feb 2017 hearing (11 pages) (10.6.17)

· Charles Jameson expert report (77 pages) (10.6.17)

· Deposition of Chadi Nabhan (138 pages) (10.6.17)

· Alfred Neugut Deposition (131 pages) (10.6.17)

· Deposition of CHRISTOPHER Portier (139 pages) (10.6.17)

· Expert witness list for plaintiffs (2 pages) (10.6.17)

· Monsanto motion for summary judgment (53 pages) (10.6.17)

· Order on Rowland request for attorney fees (2 pages) (10.6.17)

· U.S Judicial Panel Transfer order (3 pages) (10.4.17)

· Deposition of IARC member Charles W. Jameson (308 pages) (10.3.17)

· Judge denies Monsanto motion to reopen expert witness deposition (1 page) (10.2.17)

· Conditional Transfer Order Oct. 2 (2 pages) (10.2.17)

· Monsanto answer to complaint Mary L. Koehn v. Monsanto Co., (34 pages) (9.29.17)

· Discovery dispute over expert witness Dennis D. Weisenburger (20 pages) (9.26.17)

· All judges invited to Daubert (1 page) (9.20.17)

· Amended Protective Order (13 pages) (9.6.17)

· Jess Rowland response regarding his request attorneys fees (6 pages) (9.5.17)

· Judge pretrial order on Baum Hedlund (1 page) (9.1.17)

· Order Allowing Extension on Submission of Proposed New Protective Order (3 page) (8.31.17)

· Conditional Transfer Order (2 pages) (8.31.17)

· Deposition of Jess Rowland (18 pages) (8.29.17)

· Monsanto’s Response to Baum Hedlund Post-Hearing Brief (5 pages) (8.29.17)

· Exhibit Mary Manibusan correspondence with Monsanto (4 pages) (8.29.17)

· Exhibit- EPA correspondence on glyphosate (7 pages) (8.29.17)

· EXHIBIT EPA notes to Jess Rowland upon retirement (5 pages) (8.29.17)

· Exhibit Lawyer correspondence over Rowland deposition (6 pages) (8.29.17)

· Plaintiffs opposition to Jess Rowland request for attorneys fees (20 pages) (8.29.17)

· Baum Hedlund supplemental brief (6 pages) (8.28.17)

· Aug 24, 2017 transcript document dispute hearing (102 pages) (8.26.17)

· Notice of Appearance by RFJ Jr. (3 pages) (8.23.17)

· Exhibit Baycol Product Order (2 pages) (8.17.17)

· Exhibit Delaware Protective Order (23 pages) (8.17.17)

· Exhibit Monsanto’s Delaware Response to Plaintiffs’ Motion for Protective Order (10 pages) (8.17.17)

· Delaware Motion for Entry of a Protective and Confidentiality Order (10 pages) (8.17.17)

· Exhibit Transcript of Proceedings Nov. 16, 2016 (3 pages) (8.17.17)

· Attachment 2 Request for Production (3 pages) (8.17.17)

· Attachment 1 Proposed Amended Protective and Confidentiality Order (14 pages) (8.17.17)

· Monsanto’s Response to Plaintiffs Counsel Responses to Order to Show Cause (16 pages) (8.17.17)

· Jess Rowland motion for attorneys fees (24 pages) (8.15.17)

· Letter from Baum Hedlund to EPA OIG (4 pages) (8.14.17)

· Letter from Baum Hedlund to OEHHA (5 pages) (8.14.17)

· Letter from Baum Hedlund to Members of European Parliament (4 pages) (8.14.17)

· Exhibit -Communications between opposing counsel regarding Monsanto documents (8 pages) (8.14.17)

· Exhibit to Baum Hedlund response to motion to show cause (5 pages) (8.14.17)

· Declaration of Brent Wisner (15 pages) (8.14.17)

· Plaintiffs attorney Brent Wisner and Baum Hedlund response to order to show cause (19 pages) (8.14.17)

· Response of Plaintiffs Attorney Michael Miller to PTO-28 (4 pages) (8.14.17)

· Robin Greenwald response to order to show cause regarding release of Monsanto documents (11 pages) (8.14.17)

· Exhibit 4 Andrus Wagstaff response on release of Monsanto documents (2 pages) (8.14.17)

· Exhibit 3 Andrus Wagstaff response on release of Monsanto documents (31 pages) (8.14.17)

· Exhibit 2 Andrus Wagstaff response on release of Monsanto documents (5 pages) (8.14.17)

· Exhibit 1 Andrus Wagstaff response on release of Monsanto documents (5 pages) (8.14.17)

· Aimee Wagstaff declaration regarding release of Monsanto documents (7 pages) (8.14.17 )

· Andrus Wagstaff response on release of Monsanto documents (4 pages) (8.14.17)

· T ranscript of Aug. 9, 2017 teleconference hearing over release of discovery documents (10 pages) (8.11.17)

· Pretrial Order to Show Cause Re De-Designation (2 pages) 8.9.17)

· Monsanto Exhibit-Letter from plaintiffs’ attorneys to OIG (4 pages) (8.8.17)

· Monsanto Exhibit-Letter from plaintiffs’ attorneys to OEHAA (5 pages( (8.8.17)

· Monsanto Exhibit-Letter from plaintiffs’ attorneys to European Parliament (4 pages) (8.8.17)

· Monsanto’s reply, Exhibit 6 (8 pages) (8.8.17)

· Emails between plaintiffs’ and defense’s attorneys (3 pages) (8.8.17)

· Monsanto’s Reply in Support of Application for Emergency Relief (7 pages) (8.8.17)

· Plaintiffs’ attorneys’ June 30, 2017 letter to Monsanto attorneys regarding documents (31 pages) (8.5.17)

· Opposition to Monsanto Company’s Application for Emergency Relief (15 pages) (8.5.17)

· Joint Stipulation and Order Regarding Remand to State Court(5 pages) (8.3.17)

· U.S. Judicial Panel on Multidistrict Litigation Transfer Order (3 pages) (8.3.17)

· Pretrial Order: Requesting Response to Emergency Motion (1 page) (8.2.17)

· Monsanto Company’s application for emergency relief (14 pages) (8.2.17)

· Notice of Motion and Motion to Clarify Rulings Related to Confidentiality of Documents (67 pages) (8.1.17)

· Monsanto executive William Heydens’ edits and comments on expert consultant manuscript (54 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto executive William Heydens on ghostwriting chapter in expert panel manuscript (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto contributions to expert panel manuscript (39 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto executive William Heydens’ involvement in drafting expert panel manuscript (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto involvement with scientific studies (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto consultant on ghostwriting (7 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Plan for seeking retraction of Seralini study (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto scientist David Saltmiras on effort to retract Seralini study (9 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Bruce Chassy to Food and Chemical Toxicology editor on Seralini study retraction (5 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto consulting agreement with Food and Chemical Toxicology editor (1 page) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto’s intention to pay Food and Chemical Toxicology editor as consultant (1 page) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto’s relationship with Food and Chemical Toxicology editor (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto email on attempt to seek retraction of Seralini study (6 pages (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto involvement in retraction of Seralini study (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto scientist Charles Healy recommends rejection of study finding adverse effects of glyphosate and Roundup (5 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto scientist Charles Healy asked colleagues to review study finding adverse effects of glyphosate and Roundup (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto email on science concluding Roundup causes adverse health effects (1 page) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto scientist on ghostwriting cancer review paper (1 page) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Editor of journal that published expert panel manuscript states panel’s intention was to discredit IARC (73 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto scientist Donna Farmer on glyphosate studies (47 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto effort to preemptively criticize IARC in the media ahead of glyphosate report (3 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto ghostwriting article criticizing IARC (11 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email regarding Monsanto paid consultant and expert panel of independent scientists (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email regarding Monsanto individuals on expert panel (3 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Invoice showing Monsanto paid 20k to expert panel member Dr. John Acquavella (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs) (Discovery document not filed in court but provided by plaintiffs)

· Email regarding Dr. Acquavella’s consultancy for Monsanto (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Internal Monsanto email: you cannot say that Roundup is not a carcinogen (3 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Internal email: Monsanto regarding lack of testing of carcinogenicity of Roundup formulation (6 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto internal email regarding concern over plausibility of Roundup formulation carcinogenicity (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Toxicologist discusses reluctance to conduct studies on glyphosate (3 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto internal email: employee discusses lack of testing of Roundup (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Farm family exposure task force discussion of exposure study(9 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto consultant: you can’t say that there is no evidence of Roundup carcinogenicity (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto PowerPoint presentation (7 pages) (8.1.17)

· Monsanto says vulnerability ahead of IARC in epidemiology, exposure, genotoxicity and mode of action (1 page) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto internal email discussion of low level presence of formaldehyde in Roundup and other issues faced in mid 1980s (1 page) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto executive writes vulnerable on surfactants formulated product does the damage (5 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email discussion of reports and publications regarding mutagenicity of glyphosate (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email regarding Intertek work and Monsanto comments regarding formulated Roundup and tumor production (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto executive expresses concerns over IARC testing of glyphosate (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Internal email from 2008: Monsanto executive regarding NGO and research showing link to non-Hodgkin lymphoma (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Internal email regarding retest of two surfactants (6 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto PowerPoint regulatory leadership meetings (20 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto internal email discussion of formaldehyde in glyphosate and registration (6 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto consultant email regarding BfR review of glyphosate findings in human urine (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto 2002 dermal absorption study discussion (36 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email chain regarding dermal absorption studies potential to blow Roundup risk evaluations (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto personnel: further study on glyphosate absorption(3 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto discussion of 3 unexplained deaths in acute inhalation tests of lab animals (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Acute nose-only inhalation toxicity study in rats (77 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto wants to change EPA risk assessment process cites Trojan Horse (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· GI tract study: absorption in the gastrointestinal tract (3 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto Europe glyphosate excretion kinetics dermal uptake strategy (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Ethylene glycol paper (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto discussion of product database poison control information for children (5 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Dermal penetration studies discussion (5 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto Europe dermal penetration study argumentation for applicability (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email details operator exposure level when spraying Roundup under UK conditions (23 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Text messages (10 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto communications with EPA (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto worries about ATSDR glyphosate review, seeks to rebut IARC (8 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email regarding meeting with Jess Rowland and hopes he won’t check with product manager (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email regarding EPA and Monsanto meeting February 2016 on SAP (3 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Communication between Monsanto and key EPA official Jack Housenger regarding potential government review of glyphosate (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto talking points in preparation for meeting with EPA director (3 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email mentioning EPA official Jess Rowland (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto PowerPoint for State of California on glyphosate No Significant Risk Level (33 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto scientist David Saltmiras email communication on glyphosate expert panel follow-up meeting (3 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email with Exponent regarding glyphosate (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Internal Monsanto document goals to demonstrate safety of glyphosate after IARC (3 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto suggestion of Jess Rowland to glyphosate panel (16 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto email with CropLife on concerns about EPA setting SAP on glyphosate (6 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto email detailing lobbying effort to pressure WHO over IARC glyphosate classification (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email discussion of glyphosate and medical toxicologists in Europe and questions of money (9 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Internal Monsanto email regarding French ban of POEA (5 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Document details Monsanto’s strategy regarding IARC (6 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Email update on proposed meeting to discuss action on IARC in Canada (4 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Monsanto emails regarding glyphosate litigation messaging (2 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· List of studies IARC relied on for glyphosate monograph (8 pages) (8.1.17) (Discovery document not filed in court but provided by plaintiffs)

· Conditional Transfer Order (CTO −28) (2 pages) (7.27.17)

· Osborn & Barr Defendants’ Memorandum in Support of Motion to Dismiss for Failure to State a Claim (15 pages) (7.19.17)

· Letter from four Members of the European Parliament requesting access to certain transcripts and documents (3 pages) (7.13.17)

· Monsanto’s notice of appeal and representation statement (5 pages) (7.6.17)

· Order granting motion to remand (3 pages) (7.5.17)

· Videotaped deposition of John Acquavella PhD, day 1 redacted(146 pages) (Discovery document not filed in court but provided by plaintiffs) (7.3.17)

· Videotaped deposition of Matthew Ross PhD (315 pages) (Discovery document not filed in court but provided by plaintiffs) (7.3.17)

· Videotaped deposition of Aaron Earl Blair, Ph.D. (301 pages) and exhibits 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19A, 19B, 20, 21, 22, 23, 24, 25, 26, 27, 28. (Discovery documents not filed in court but provided by plaintiffs) (6.16.17)